Interleukin plan rejected by NYSE Amex - Atlanta Business Chronicle:

sunrise-invoices.blogspot.com
Interleukin (NYSE Amex: ILI) has appealede the decision, made March 27, and asker for a hearing with NYSE officials. That meeting is expected to be set within the next 45 The company disclosed the listing decision and appeal in a regulatoryfilingb Tuesday. In December, Interleukin, based in Mass., received notice from the NYSE that it was no longerd in compliance with itslisting standards, as the company’ws stockholders equity had fallen belo the $6 million threshold. Interleukin’s five-consecutive quarters of net losses as well as losses from operations also violatecd theNYSE Amex’s compliancre rules. As of Dec.
31, Interleukin’s stockholders’ equity was valued at around $4.5 million. Interleukih develops diagnostic technologies, such as biomarker tests, for the personal healtyh care market.